Aytu Biopharma EV/EBIT AYTU

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2022.

Today, Oct 23, 2026: n/m; an operating loss
Last meaningful: 262×; Jan 2026
4-year median: 4.5×
4-year range: 0.0× to 336×
Peer median: 2.1×

Aytu Biopharma has no meaningful EV/EBIT today: it made an operating loss of $8.3M over the last twelve months.

It was last meaningful in Jan 2026, at 262×.

On the days it had one over the last 4 years, its median was 4.5×, from 0.0× in Feb 2023 to 336× in Jan 2026.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	262×	262×	336×
2025	197×	0.5×	241×
2024	6.0×	5.1×	33.6×
2023	0.3×	0.0×	0.5×
2022	0.1×	0.1×	1.1×

Against its peers

Companies in Drug Manufacturers - General nearest Aytu Biopharma's size, closest first, today.

Company	EV/EBIT
AYTUAytu Biopharma	n/m
ATNMActinium Pharmaceuticals	1.2×
SPROSpero Therapeutics	2.1×
LFVNLifevantage	9.6×
Peer median	2.1×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Aytu Biopharma

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.